## Andrew V Schally

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7790606/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Physiological role of somatostatin in the control of growth hormone and thyrotropin secretion. Biochemical and Biophysical Research Communications, 1976, 68, 149-156.	2.1	269
2	CNS effects of peripherally administered brain peptides. Life Sciences, 1979, 25, 401-414.	4.3	269
3	Transplantation of human islets without immunosuppression. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 19054-19058.	7.1	261
4	Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses. Biochemical and Biophysical Research Communications, 1971, 44, 459-463.	2.1	246
5	Isolation and structure of hypothalamic MSH release-inhibiting hormone. Biochemical and Biophysical Research Communications, 1971, 43, 1376-1381.	2.1	238
6	Hypothalamic Hormones and Cancer. Frontiers in Neuroendocrinology, 2001, 22, 248-291.	5.2	235
7	The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Human Reproduction, 1994, 9, 1364-1379.	0.9	231
8	Synthesis of the porcine LH- and FSH-releasing hormone by the solid-phase method. Biochemical and Biophysical Research Communications, 1971, 45, 822-827.	2.1	230
9	Isolation of Gamma-Amino Butyric Acid from Pig Hypothalami and Demonstration of its Prolactin Release-Inhibiting (PIF) Activityin VivoandinVitro*. Endocrinology, 1977, 100, 681-691.	2.8	221
10	Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesisâ~†. Peptides, 1999, 20, 1247-1262.	2.4	217
11	Characteristics and distribution of receptors for [dâ€ŧrp <sup>6</sup> ]―luteinizing hormoneâ€ŧeleasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. Journal of Clinical Laboratory Analysis, 1989, 3, 137-147.	2.1	206
12	Immunocytochemical Localization of Growth Hormone-Releasing Factor in the Rat Hypothalamus*. Endocrinology, 1984, 114, 1082-1085.	2.8	192
13	Chemotherapy targeted to cancers through tumoral hormone receptors. Trends in Endocrinology and Metabolism, 2004, 15, 300-310.	7.1	191
14	Inhibition of testicular luteinizing hormone receptor level by treatment with a potent luteinizing hormone-releasing hormone agonist or human chorionic gonadotropin. Biochemical and Biophysical Research Communications, 1977, 76, 855-862.	2.1	187
15	Isolation and structure of somatostatin from porcine hypothalami. Biochemistry, 1976, 15, 509-514.	2.5	186
16	DOPA Potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). Life Sciences, 1971, 10, 1279-1283.	4.3	182
17	Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 33-43.	2.8	179
18	Synthetic Thyrotropin-Releasing Hormone. New England Journal of Medicine, 1971, 285, 1279-1283.	27.0	178

#	Article	IF	CITATIONS
19	Hypothalamic Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH)-Regulating Hormone: Structure, Physiology, and Clinical Studies. Fertility and Sterility, 1971, 22, 703-721.	1.0	177
20	Immunohistological study of the origin of LH-RH-containing nerve fibers of the rat hypothalamus. Brain Research, 1976, 103, 597-602.	2.2	174
21	Suppression of Prolactin Release by a Purified Porcine PIF Preparation and Catecholamines Infused into a Rat Hypophysial Portal Vessel. Endocrinology, 1974, 95, 462-465.	2.8	163
22	Inhibition of adenosine 3′,5′-monophosphate accumulation in anterior pituitary gland in vitro by growth hormone-release inhibiting hormone. Biochemical and Biophysical Research Communications, 1974, 56, 1052-1059.	2.1	162
23	HIGH INCIDENCE OF RECEPTORS FOR LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AND LHRH RECEPTOR GENE EXPRESSION IN HUMAN PROSTATE CANCERS. Journal of Urology, 2000, 163, 623-629.	0.4	161
24	Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5022-5027.	7.1	160
25	Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: Internalization of receptor bound125I-(Tyr4) bombesin by tumor cells. Prostate, 1994, 25, 29-38.	2.3	158
26	Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate, 2000, 42, 295-303.	2.3	150
27	Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. Journal of Medicinal Chemistry, 1976, 19, 423-425.	6.4	148
28	Effect of Growth Hormone Release-Inhibiting Hormone on Gastric Secretion, Mucosal Blood Flow, and Serum Gastrin. Gastroenterology, 1976, 70, 737-741.	1.3	147
29	Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 157-167.	2.8	142
30	Isolation of the Luteinizing Hormone and Follicle-stimulating Hormone-releasing Hormone from Porcine Hypothalami. Journal of Biological Chemistry, 1971, 246, 7230-7236.	3.4	142
31	Affective State and Thyrotropin and Prolactin Responses After Repeated Injections of Thyrotropin-Releasing Hormone in Depressed Patients. American Journal of Psychiatry, 1974, 131, 714-718.	7.2	138
32	Electron microscopic immunohistochemical localization of growth hormone-release inhibiting hormone (somatostatin) in the rat median eminence. American Journal of Anatomy, 1974, 140, 445-450.	1.0	134
33	Mechanisms of Antineoplastic Action of Somatostatin Analogs. Experimental Biology and Medicine, 1998, 217, 143-152.	2.4	134
34	Antagonistic Analogs of Growth Hormone-releasing Hormone: New Potential Antitumor Agents. Trends in Endocrinology and Metabolism, 1999, 10, 383-391.	7.1	134
35	Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate, 1989, 14, 191-208.	2.3	130
36	Enkephalin and a potent analog facilitate maze performance after intraperitoneal administration in rats. Pharmacology Biochemistry and Behavior, 1976, 5, 691-695.	2.9	128

#	Article	IF	CITATIONS
37	Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Letters, 1985, 179, 252-256.	2.8	127
38	Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers1. Biology of Reproduction, 2005, 73, 851-859.	2.7	126
39	MIF-I's differential actions as an opiate antagonist. Pharmacology Biochemistry and Behavior, 1979, 11, 721-723.	2.9	125
40	New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analogues. International Journal of Peptide and Protein Research, 1988, 32, 425-435.	0.1	123
41	Psycho-physiologic correlates of MSH activity in man. Physiology and Behavior, 1971, 7, 893-896.	2.1	121
42	Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 155-160.	7.1	117
43	Antitumor Effects of Analogs of Hypothalamic Hormones in Endocrine-Dependent Cancers. Experimental Biology and Medicine, 1984, 175, 259-281.	2.4	113
44	Evaluation of Receptors for Somatostatin in Various Tumors Using Different Analogs*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 661-669.	3.6	113
45	sst2 Somatostatin Receptor Mediates Cell Cycle Arrest and Induction of p27. Journal of Biological Chemistry, 1999, 274, 15186-15193.	3.4	112
46	Isolation of thyrotropin releasing factor (TRF) from porcine hypothalamus. Biochemical and Biophysical Research Communications, 1966, 25, 165-169.	2.1	111
47	The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 17424-17429.	7.1	110
48	Peptide analogs in the therapy of prostate cancer. Prostate, 2000, 45, 158-166.	2.3	109
49	Release of LH and FSH after Administration of Synthetic LH-Releasing Hormone*. Journal of Clinical Endocrinology and Metabolism, 1972, 34, 753-756.	3.6	108
50	Distribution of 3H-α-MSH in rat brain. Brain Research Bulletin, 1976, 1, 19-26.	3.0	108
51	Growth-Inhibitory Actions of Analogues of Luteinizing Hormone Releasing Hormone on Tumor Cells. Trends in Endocrinology and Metabolism, 1997, 8, 355-362.	7.1	107
52	New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sciences, 2003, 72, 2305-2320.	4.3	105
53	Assays for Corticotropin-Releasing Factor (CRF) Using Rats Treated with Morphine, Chlorpromazine, Dexamethasone and Nembutal. Endocrinology, 1967, 81, 235-245.	2.8	104
54	<i>cKit</i> <sup>+</sup> cardiac progenitors of neural crest origin. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13051-13056.	7.1	104

#	Article	IF	CITATIONS
55	Gonadotropin and <i>α</i> -Subunit Secretion During Long Term Pituitary Suppression by <scp>D</scp> -Trp <sup>6</sup> -Luteinizing Hormone-Releasing Hormone Microcapsules as Treatment of Precocious Puberty*. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 946-953.	3.6	103
56	Potent prolactin and growth hormone releasing activity of more analogues of Met-enkephalin. Nature, 1977, 268, 544-547.	27.8	100
57	Localization of growth hormone-release-inhibiting hormone (somatostatin) in the rat brain. American Journal of Anatomy, 1975, 142, 397-401.	1.0	98
58	Expression of Growth Hormone-Releasing Hormone (GHRH) Messenger Ribonucleic Acid and the Presence of Biologically Active GHRH in Human Breast, Endometrial, and Ovarian Cancers1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 582-589.	3.6	96
59	Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2604-2609.	7.1	95
60	Neuropharmacological actions of enkephalin after systemic administration. Life Sciences, 1976, 19, 1283-1288.	4.3	94
61	Solid phase synthesis of growth hormone-release inhibiting factor. Biochemical and Biophysical Research Communications, 1973, 54, 1267-1273.	2.1	92
62	Synthesis and biological properties of [D-Ala-6, des-Gly-NH2-10]-LH-RH ethylamide, a peptide with greatly enhanced LH- and FSH-releasing activity. Biochemical and Biophysical Research Communications, 1974, 57, 335-340.	2.1	92
63	Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate, 1994, 24, 84-92.	2.3	92
64	Blockade of the Preovulatory Surge of LH and FSH and of Ovulation by Anti-LH-RH Serum in Rats. Endocrinology, 1974, 95, 323-324.	2.8	91
65	Enkephalin and other peptides reduce passiveness. Pharmacology Biochemistry and Behavior, 1978, 9, 515-519.	2.9	91
66	Antitumor effects of the cytotoxic luteinizing hormone–releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. American Journal of Obstetrics and Gynecology, 2002, 187, 528-537.	1.3	91
67	Blood-brain barrier, half-time disappearance, and brain distribution for labeled enkephalin and a potent analog. Brain Research Bulletin, 1976, 1, 583-589.	3.0	89
68	<i>S</i> -nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2834-2839.	7.1	89
69	LHâ€RH Agonists and Antagonists. International Journal of Gynecology and Obstetrics, 1980, 18, 318-324.	2.3	88
70	AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opinion on Investigational Drugs, 2012, 21, 891-899.	4.1	86
71	Synthesis and biological properties of [Leu-6]-LH-RH and [D-leu-6,desCly-NH210]-LH-RH ethylamide. Biochemical and Biophysical Research Communications, 1974, 59, 1226-1232.	2.1	85
72	Growth hormone-releasing hormone: Extrapituitary effects in physiology and pathology. Cell Cycle, 2010, 9, 4110-4116.	2.6	85

#	Article	IF	CITATIONS
73	Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 11745-11750.	7.1	85
74	Changes in Pituitary Responsiveness to Luteinizing Hormone-Releasing Hormone (LH-RH) in Anestrous Ewes Pretreated with Estradiol Benzoate1. Biology of Reproduction, 1971, 4, 88-92.	2.7	82
75	Growth hormone-releasing hormone: not only a neurohormone. Trends in Endocrinology and Metabolism, 2011, 22, 311-317.	7.1	82
76	Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22269-22274.	7.1	81
77	Effect of somatostatin on the proliferation of mouse spleen lymphocytes in, vitro. Biochemical and Biophysical Research Communications, 1985, 129, 52-55.	2.1	79
78	Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160. Prostate, 1992, 20, 269-280.	2.3	79
79	Additional evidence that small amounts of a peptide can cross the blood-brain barrier. Pharmacology Biochemistry and Behavior, 1979, 11, 717-719.	2.9	78
80	Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. International Journal of Cancer, 1994, 57, 574-580.	5.1	78
81	New Approaches to the Therapy of Various Tumors Based on Peptide Analogues. Hormone and Metabolic Research, 2008, 40, 315-322.	1.5	78
82	The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11866-11871.	7.1	77
83	P53, GHRH, inflammation and cancer. EBioMedicine, 2018, 37, 557-562.	6.1	77
84	The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers. Regulatory Peptides, 2000, 90, 77-84.	1.9	76
85	Stimulation of LH Release in Men and Women by LH-Releasing Hormone Purified from Porcine Hypothalami. Journal of Clinical Endocrinology and Metabolism, 1969, 29, 1046-1050.	3.6	74
86	Electroencephalographic measures of melanocyte-stimulating hormone activity Journal of Comparative and Physiological Psychology, 1971, 76, 103-109.	1.8	73
87	Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 196-200.	7.1	73
88	Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters events that accompany tumor regression. Cancer, 1990, 65, 2279-2290.	4.1	72
89	Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. International Journal of Cancer, 1993, 55, 963-967.	5.1	71
90	Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Human Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4707-4714.	3.6	71

#	Article	IF	CITATIONS
91	PEPTIDE ANTAGONISTS OF LH-RH: LARGE INCREASES IN ANTIOVULATORY ACTIVITIES PRODUCED BY BASIC D-AMINO ACIDS IN THE SIX POSITION. Endocrinology, 1982, 110, 1445-1447.	2.8	70
92	Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1250-1255.	7.1	70
93	Comparison of Different Agonists and Antagonists of Luteinizing Hormone-Releasing Hormone for Receptor-Binding Ability to Rat Pituitary and Human Breast Cancer Membranes*. Endocrinology, 1989, 124, 946-955.	2.8	69
94	Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Research and Treatment, 2000, 60, 71-79.	2.5	69
95	Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3755-3760.	7.1	69
96	Acceleration of wound healing by growth hormone-releasing hormone and its agonists. Proceedings of the United States of America, 2010, 107, 18611-18615.	7.1	67
97	LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate, 2011, 71, 736-747.	2.3	66
98	Transplantation of bovine adrenocortical cells encapsulated in alginate. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2527-2532.	7.1	66
99	High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2564-2571.	3.6	65
100	Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone. Fertility and Sterility, 1987, 48, 383-389.	1.0	64
101	Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20470-20475.	7.1	64
102	Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12623-12628.	7.1	64
103	Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1655-1660.	7.1	64
104	Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate, 1983, 4, 545-552.	2.3	63
105	Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with Nâ€ŧerminal <scp>d</scp> â€ᠯrp or <scp>d</scp> â€ᠯpi. International Journal of Peptide and Protein Research, 1991, 38, 593-600.	0.1	63
106	The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 183-191.	1.6	63
107	Radioimmunoassay of DSIP-like material in rat brain. Brain Research Bulletin, 1978, 3, 691-695.	3.0	62
108	Recent Approaches to Fertility Control Based on Derivatives of LH-RH. Vitamins and Hormones, 1981, 38, 257-323.	1.7	62

#	Article	IF	CITATIONS
109	Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1–STAT3/NF.κB signaling. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14745-14750.	7.1	62
110	Acute promyelocytic leukemia (APL): a review of the literature. Oncotarget, 2020, 11, 992-1003.	1.8	62
111	Somatostatin, Its Receptors and Analogs, in Lung Cancer. Chemotherapy, 2001, 47, 78-108.	1.6	61
112	Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9512-9517.	7.1	61
113	Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors. Current Drug Delivery, 2011, 8, 11-25.	1.6	61
114	General activity in intact and hypophysectomized rats after administration of melanocyte-stimulating hormone (MSH), melatonin, and Pro-Leu-Gly-NH2. Physiology and Behavior, 1973, 10, 399-401.	2.1	60
115	Inhibition of growth hormone and thyrotropin release by growth hormone-release inhibiting hormone. Molecular and Cellular Endocrinology, 1974, 1, 329-339.	3.2	60
116	Interaction between hypothalamic peptides in a superfused pituitary cell system. Peptides, 1984, 5, 241-247.	2.4	60
117	Growth Inhibition of Estrogen-Dependent and Estrogen-Independent MXT Mammary Cancers in Mice by the Bombesin and Gastrin-Releasing Peptide Antagonist RC-3095. Journal of the National Cancer Institute, 1992, 84, 1915-1922.	6.3	60
118	Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate, 2000, 44, 172-180.	2.3	60
119	in vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215. International Journal of Cancer, 2000, 88, 652-657.	5.1	60
120	Purification of Luteinizing Hormone-Releasing Factor from Bovine Hypothalamus. Endocrinology, 1964, 75, 608-614.	2.8	59
121	Autoregulation of Release of Melanocyte Stimulating Hormone from the Rat Pituitary. Nature, 1967, 213, 1238-1240.	27.8	58
122	Highly active position eight analogs of somatostatin and separation of peptide diastereomers by partition chromatography. Biochemistry, 1978, 17, 2326-2331.	2.5	58
123	Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone. Cancer, 2002, 95, 1735-1745.	4.1	58
124	Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 559-563.	7.1	58
125	Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. Peptides, 2014, 52, 104-112.	2.4	58
126	<i>In Vitro</i> and <i>in Vivo</i> Stimulation of the Release of Luteinizing Hormone. Endocrinology, 1964, 75, 312-320.	2.8	57

#	Article	IF	CITATIONS
127	Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology, 1995, 45, 275-281.	1.0	57
128	Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma: A prospective double blind randomized trial. , 1996, 78, 1452-1460.		57
129	The Expression of Growth Hormone-Releasing Hormone (GHRH) and its Receptor Splice Variants in Human Breast Cancer Lines; The Evaluation of Signaling Mechanisms in the Stimulation of Cell Proliferation. Breast Cancer Research and Treatment, 2003, 77, 15-26.	2.5	57
130	Targeted Therapy of Breast and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones. Molecular Pharmaceutics, 2007, 4, 652-658.	4.6	57
131	Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle, 2010, 9, 1738-1741.	2.6	57
132	Growth hormone release inhibiting hormone: Neuropharmacological studies. Pharmacology Biochemistry and Behavior, 1974, 2, 693-696.	2.9	56
133	Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release. Biochemical and Biophysical Research Communications, 1977, 74, 630-636.	2.1	56
134	Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis. American Journal of Obstetrics and Gynecology, 1994, 170, 96-102.	1.3	56
135	Administration of LH-releasing hormone to selected subjects. American Journal of Obstetrics and Gynecology, 1970, 108, 177-182.	1.3	55
136	Corticotropin Releasing Factor (CRF): Immunocytochemical localization and Radioimmunoassay (RIA). Life Sciences, 1982, 31, 2441-2448.	4.3	54
137	Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. , 1997, 32, 164-172.		54
138	Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Cancer, 1998, 83, 1335-1343.	4.1	54
139	Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from <i>in Vitro</i> Studies on Human Prostatic and Pancreatic Cancers <sup>1</sup> . Endocrinology, 2000, 141, 2120-2128.	2.8	54
140	Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anti-Cancer Drugs, 2001, 12, 761-768.	1.4	54
141	Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors. Gynecologic Oncology, 2010, 119, 457-461.	1.4	54
142	Successful Induction of Ovulation with Synthetic Luteinizing Hormone-Releasing Hormone in Anovulatory Infertility. Fertility and Sterility, 1972, 23, 672-674.	1.0	53
143	Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system. American Journal of Obstetrics and Gynecology, 2004, 191, 1164-1172.	1.3	53
144	Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20452-20457.	7.1	53

#	Article	IF	CITATIONS
145	Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. Metabolism: Clinical and Experimental, 1990, 39, 163-166.	3.4	52
146	Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice. Cancer Letters, 1993, 71, 189-196.	7.2	52
147	Effect of Catecholamines on the TRH-Stimulated Release of Prolactin and Growth Hormone from Sheep Pituitaries <i>in Vitro</i> . Endocrinology, 1974, 95, 1490-1494.	2.8	51
148	Antagonists of Growth Hormone-Releasing Hormone and Somatostatin Analog RC-160 Inhibit the Growth of the OV-1063 Human Epithelial Ovarian Cancer Cell Line Xenografted into Nude Mice1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2144-2152.	3.6	51
149	Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5575-5579.	7.1	51
150	Actions and Potential Therapeutic Applications of Growth Hormone–Releasing Hormone Agonists. Endocrinology, 2019, 160, 1600-1612.	2.8	51
151	Regulation of endometrial cancer cell growth by insulin-like growth factors and the luteinizing hormone-releasing hormone antagonist SB-75. Regulatory Peptides, 1993, 48, 91-98.	1.9	50
152	Inhibitory Effects of Antagonists of Bombesin/Gastrin Releasing Peptide (GRP) and Somatostatin Analog (RC-160) on Growth of HT-29 Human Colon Cancers in Nude Mice. Acta Oncológica, 1994, 33, 693-701.	1.8	50
153	Antagonists of Growth Hormone-Releasing Hormone in Oncology. Combinatorial Chemistry and High Throughput Screening, 2006, 9, 163-170.	1.1	50
154	Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Molecular and Cellular Endocrinology, 2009, 302, 41-48.	3.2	50
155	Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2084-2089.	7.1	50
156	CNS effects of somatostatin. Metabolism: Clinical and Experimental, 1978, 27, 1247-1252.	3.4	49
157	Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. International Journal of Cancer, 1991, 49, 260-266.	5.1	49
158	Expression of Receptors for Luteinizing Hormone-Releasing Hormone (LH-RH) in Prostate Cancers following Therapy with LH-RH Agonists. Clinical Cancer Research, 2010, 16, 4675-4680.	7.0	49
159	Pituitary and Serum FSH and LH Levels after Massive and Selective Depletion of the Germinal Epithelium in the Rat Testis*. Endocrinology, 1973, 92, 48-54.	2.8	48
160	GHRH antagonists support lung endothelial barrier function. Tissue Barriers, 2019, 7, 1669989.	3.2	48
161	Localization of corticotropin-releasing factor-containing neurons in the brain of the domestic fowl. Cell and Tissue Research, 1984, 236, 245-248.	2.9	47
162	The Binding of Bombesin and Somatostatin and Their Analogs to Human Colon Cancers. Experimental Biology and Medicine, 1992, 200, 394-401.	2.4	47

#	Article	IF	CITATIONS
163	Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. Journal of Cancer Research and Clinical Oncology, 1994, 120, 519-528.	2.5	47
164	Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2288-2293.	7.1	47
165	Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: Role of apoptosis. American Journal of Obstetrics and Gynecology, 1994, 170, 96-102.	1.3	46
166	Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers. Cancer Letters, 1999, 136, 129-136.	7.2	46
167	Enhancement of Immunoreactive Somatostatin Release into Hypophysial Portal Blood by Electrical Stimulation of the Preoptic Area in the Rat*. Endocrinology, 1979, 105, 1416-1418.	2.8	45
168	Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of U-87MG Human Glioblastoma in Nude Mice. Neoplasia, 2000, 2, 242-250.	5.3	45
169	Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-junand c-fosoncogenes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3836-3841.	7.1	45
170	Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers. Peptides, 2002, 23, 1127-1133.	2.4	45
171	Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 15836-15841.	7.1	45
172	Extrapituitary Effects of the Growth Hormone-Releasing Hormone. Vitamins and Hormones, 2005, 70, 1-24.	1.7	45
173	Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11Â-hydroxysteroid dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13722-13727.	7.1	45
174	Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World Journal of Gastroenterology, 2014, 20, 6102.	3.3	45
175	Peripheral administration of hypothalamic peptides results in CNS changes. Pharmacological Research Communications, 1978, 10, 293-312.	0.2	44
176	The presence of LHRH-like receptors in Dunning R3327H prostate tumors. FEBS Letters, 1983, 154, 92-96.	2.8	44
177	Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone—releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer, 1994, 73, 1229-1238.	4.1	44
178	Efficacy and Safety of Luteinizing Hormone-Releasing Hormone Antagonist Cetrorelix in the Treatment of Symptomatic Benign Prostatic Hyperplasia <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3826-3831.	3.6	44
179	Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. , 1999, 38, 151-158.		44
180	Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12033-12038.	7.1	44

#	Article	IF	CITATIONS
181	Stimulatory and inhibitory analogs of luteinizing hormone releasing hormone. Biochemistry, 1974, 13, 323-326.	2.5	43
182	Radioautographic localization of radioactivity in rat brain after intracarotid injection of 1251-α-melanocyte-stimulating hormone. Pharmacology Biochemistry and Behavior, 1975, 3, 671-674.	2.9	43
183	Dissociation of effects of LH-RH analogs on pituitary regulation and reproductive behavior. Pharmacology Biochemistry and Behavior, 1980, 13, 913-914.	2.9	43
184	Role of endogenous gastrin in gastroprotection. European Journal of Pharmacology, 1995, 278, 203-212.	3.5	43
185	RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3509-3512.	3.6	43
186	Effects of a growth hormone-releasing hormone antagonist on telomerase activity, oxidative stress, longevity, and aging in mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 22272-22277.	7.1	43
187	Effect of bombesin, gastrin-releasing peptide (GRP)(14–27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. International Journal of Cancer, 1993, 54, 282-289.	5.1	42
188	Antagonists of bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. International Journal of Cancer, 1995, 63, 257-262.	5.1	42
189	Synthesis and In Vitro Evaluation of New Potent Antagonists of Growth Hormone-Releasing Hormone (CH-RH). Peptides, 1997, 18, 423-430.	2.4	42
190	Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer, 2003, 98, 1401-1410.	4.1	42
191	Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate, 2005, 64, 303-315.	2.3	42
192	Targeted cytotoxic analog of luteinizing hormone–releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. American Journal of Obstetrics and Gynecology, 1999, 180, 1095-1103.	1.3	41
193	Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1708-1713.	7.1	41
194	Luteinizing Hormone-Releasing Hormone Receptor-Targeted Chemotherapy Using AN-152. Neuroendocrinology, 2009, 90, 15-18.	2.5	41
195	Antagonists of growth hormone-releasing hormone suppress <i>in vivo</i> tumor growth and gene expression in triple negative breast cancers. Oncotarget, 2012, 3, 988-997.	1.8	41
196	Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Research, 2003, 63, 7913-9.	0.9	41
197	Effect of Hypothalamic Extracts on Release of Growth Hormone in vitro. Experimental Biology and Medicine, 1965, 119, 208-212.	2.4	40
198	Prolactin and luteinizing hormone-releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer. Prostate, 1988, 12, 299-307.	2.3	40

#	Article	IF	CITATIONS
199	Antagonists of GHRH Decrease Production of GH and IGF-I in MXT Mouse Mammary Cancers and Inhibit Tumor Growth. Endocrinology, 2001, 142, 4371-4378.	2.8	40
200	Human Malignant Melanomas Express Receptors for Luteinizing Hormone Releasing Hormone Allowing Targeted Therapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogue. Cancer Research, 2005, 65, 5857-5863.	0.9	40
201	Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10403-10407.	7.1	40
202	Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1084-1089.	7.1	40
203	Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clinical Cancer Research, 2003, 9, 3742-8.	7.0	40
204	Immunomodulatory Action of Somatostatin. Annals of the New York Academy of Sciences, 1987, 496, 233-239.	3.8	39
205	Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs. Journal of Cancer Research and Clinical Oncology, 1999, 125, 444-452.	2.5	39
206	Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. , 1999, 82, 592-598.		39
207	Cellular Mechanisms of Growth Inhibition of Human Epithelial Ovarian Cancer Cell Line by LH-Releasing Hormone Antagonist Cetrorelix. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3721-3727.	3.6	39
208	Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer, 2005, 104, 1312-1321.	4.1	39
209	Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: A potential applicability to treatment of brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 12495-12500.	7.1	39
210	Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 1943-1946.	7.1	39
211	Growth hormone releasing hormone ( <scp>GHRH</scp> ) signaling modulates intermittent hypoxiaâ€induced oxidative stress and cognitive deficits in mouse. Journal of Neurochemistry, 2013, 127, 531-540.	3.9	39
212	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 6277-6283.	7.0	39
213	Immunohistological detection of degenerating CRF-immunoreactive nerve fibers in the median eminence after lesion of paraventricular nucleus of the rat. A light and electron microscopic study. Peptides, 1983, 4, 941-953.	2.4	38
214	Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent dunning R-3327-AT-1 rat prostate cancer. International Journal of Cancer, 1994, 59, 51-55.	5.1	38
215	Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. European Journal of Cancer, 2005, 41, 2735-2744.	2.8	38
216	Release of peptides from sustained delivery systems (microcapsules and microparticles) <i>in vivo</i> . International Journal of Peptide and Protein Research, 1990, 35, 557-565.	0.1	38

#	Article	IF	CITATIONS
217	Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18303-18308.	7.1	38
218	Multimodal Somatostatin Receptor Theranostics Using [ <sup>64</sup> Cu]Cu-/[ <sup>177</sup> Lu]Lu-DOTA-(Tyr <sup>3</sup> )octreotate and AN-238 in a Mouse Pheochromocytoma Model. Theranostics, 2016, 6, 650-665.	10.0	38
219	Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. Peptides, 2017, 89, 60-70.	2.4	38
220	Role of tryptophan in the luteinizing hormone-releasing hormone. Biochemistry, 1974, 13, 3550-3553.	2.5	37
221	Somatostatin Analogue RC-160 and LH-RH Antagonist SB-75 Inhibit Growth of MIA PaCa-2 Human Pancreatic Cancer Xenografts in Nude Mice. Pancreas, 1993, 8, 88-97.	1.1	37
222	CHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle, 2009, 8, 3149-3156.	2.6	37
223	Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clinical Cancer Research, 2003, 9, 4505-13.	7.0	37
224	DSIP $\hat{a} \in \mathbb{C}^{n}$ more than a sleep peptide?. Trends in Neurosciences, 1980, 3, 163-165.	8.6	36
225	Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75). European Journal of Endocrinology, 1994, 131, 286-292.	3.7	36
226	Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15048-15053.	7.1	36
227	Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate, 2002, 52, 173-182.	2.3	36
228	Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins. Endocrine-Related Cancer, 2005, 12, 999-1009.	3.1	36
229	Receptors for Luteinizing Hormone Releasing Hormone Expressed on Human Renal Cell Carcinomas Can Be Used for Targeted Chemotherapy with Cytotoxic Luteinizing Hormone Releasing Hormone Analogues. Clinical Cancer Research, 2005, 11, 5549-5557.	7.0	36
230	An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. OncoTargets and Therapy, 2013, 6, 391.	2.0	36
231	Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 17260-17265.	7.1	36
232	Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields. Nanomedicine, 2018, 13, 423-438.	3.3	36
233	Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease. Aging, 2012, 4, 755-767.	3.1	36
234	Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Research, 2002, 62, 781-8.	0.9	36

#	Article	IF	CITATIONS
235	Neonatal administration of met-enkephalin facilitates maze performance of adult rats. Pharmacology Biochemistry and Behavior, 1980, 13, 883-886.	2.9	35
236	Isolation and structure of several peptides from porcine hypothalami. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1980, 625, 266-273.	1.7	35
237	Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. International Journal of Cancer, 1992, 52, 791-796.	5.1	35
238	Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) on GH and Insulin-Like Growth Factor I Levels in Transgenic Mice Overexpressing the Human GHRH Gene, an Animal Model of Acromegaly*. Endocrinology, 1997, 138, 4536-4542.	2.8	35
239	Luteinizing hormone–releasing hormone (LH–RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regulatory Peptides, 1998, 77, 185-192.	1.9	35
240	Inhibition of Growth of Experimental Human Endometrial Cancer by an Antagonist of Growth Hormone-Releasing Hormone. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3614-3621.	3.6	35
241	Isolation and characterization of adrenocortical progenitors involved in the adaptation to stress. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12997-13002.	7.1	35
242	Naloxone-like actions of MIF-1 do not require the presence of the pituitary. Pharmacology Biochemistry and Behavior, 1980, 13, 907-912.	2.9	34
243	Anovulatory effect of a LHRH antagonist in women. Contraception, 1981, 24, 315-320.	1.5	34
244	Synthesis and biological activity of LH-RH antagonists modified in position 1. Peptides, 1982, 3, 969-971.	2.4	34
245	Effects of the LHRH antagonist Cetrorelix on the brain function in mice. Neuropeptides, 2009, 43, 229-234.	2.2	34
246	GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Letters, 2010, 293, 31-40.	7.2	34
247	Androgen Deficiency and Dry Eye Syndrome in the Aging Male. , 2014, 55, 5046.		34
248	Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1359-1364.	7.1	34
249	Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13248-13253.	7.1	34
250	Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Research and Treatment, 1989, 14, 307-314.	2.5	33
251	Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi. Peptides, 1992, 13, 267-271.	2.4	33
252	Hypothalamic hormones. Anti-Cancer Drugs, 1994, 5, 115-130.	1.4	33

15

#	Article	IF	CITATIONS
253	Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway. , 1996, 68, 528-534.		33
254	Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice. Breast Cancer Research and Treatment, 2000, 59, 255-262.	2.5	33
255	Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Letters, 2002, 176, 57-63.	7.2	33
256	Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3435-3440.	7.1	33
257	Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14513-14518.	7.1	33
258	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17769-17774.	7.1	33
259	Mechanisms of inhibition of human benign prostatic hyperplasia <i>in vitro</i> by the luteinizing hormoneâ€releasing hormone antagonist cetrorelix. BJU International, 2010, 106, 1382-1388.	2.5	33
260	Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13651-13656.	7.1	33
261	Dose-Response relationship of luteinizing hormone to luteinizing hormone—releasing hormone in man. Journal of Clinical Investigation, 1971, 50, 1551-1553.	8.2	33
262	Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 (AEZS-108). Oncotarget, 2012, 3, 686-699.	1.8	33
263	Paradoxical Effects of d-Trp6-Luteinizing Hormone-Releasing Hormone on the Hypothalamic-Pituitary-Gonadal Axis in Immature Female Rats. Fertility and Sterility, 1979, 31, 677-682.	1.0	32
264	Somatostatin analogue rc-160 inhibits the growth of transplanted colon cancer in rats. International Journal of Cancer, 1991, 47, 765-770.	5.1	32
265	Characterization of bombesin/gastrin-releasing peptide receptors in membranes of MKN45 human gastric cancer. Cancer Letters, 1994, 85, 111-118.	7.2	32
266	Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. Advanced Drug Delivery Reviews, 1997, 28, 157-169.	13.7	32
267	Inhibition of the growth of caki-I human renal adenocarcinoma in Vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer, 1998, 82, 909-917.	4.1	32
268	Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma a431 cells. International Journal of Cancer, 2002, 99, 505-513.	5.1	32
269	Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2, and pAkt. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18671-18676.	7.1	32
270	Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer, 2008, 112, 1404-1414.	4.1	32

#	Article	IF	CITATIONS
271	Combining Growth Hormone-Releasing Hormone Antagonist With Luteinizing Hormone-Releasing Hormone Antagonist Greatly Augments Benign Prostatic Hyperplasia Shrinkage. Journal of Urology, 2012, 187, 1498-1504.	0.4	32
272	Growth Hormone-Releasing Hormone in Diabetes. Frontiers in Endocrinology, 2016, 7, 129.	3.5	32
273	Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clinical Cancer Research, 2005, 11, 49-57.	7.0	32
274	Activity of VIP, somatostatin and other peptides in the mouse vas deferens assay. Pharmacology Biochemistry and Behavior, 1978, 9, 673-676.	2.9	31
275	Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Research and Treatment, 1992, 21, 35-45.	2.5	31
276	Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. European Journal of Cancer, 2005, 41, 2196-2202.	2.8	31
277	Doseâ€dependent growth inhibition in vivo of PCâ€3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZâ€Jâ€7â€138. Prostate, 2008, 68, 1763-1772.	2.3	31
278	Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. Cancer Letters, 2010, 294, 35-42.	7.2	31
279	Novel antagonists of growth hormoneâ€releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer, 2012, 118, 670-680.	4.1	31
280	Regulation of Vascular Calcification by Growth Hormone–Releasing Hormone and Its Agonists. Circulation Research, 2018, 122, 1395-1408.	4.5	31
281	DISAPPEARANCE OF LHâ€RELEASING HORMONE IN MAN AS DETERMINED BY RADIOIMMUNOASSAY. Clinical Endocrinology, 1974, 3, 421-425.	2.4	30
282	Recovery of Pituitary-Gonadal Function in Male and Female Rats after Prolonged Administration of a Potent Antagonist of Luteinizing Hormone-Releasing Hormone (SB-75). Neuroendocrinology, 1991, 54, 136-145.	2.5	30
283	Saturable efflux of the peptides RC-160 and Tyr-MIF-1 by different parts of the blood-brain barrier. Brain Research Bulletin, 1994, 35, 179-182.	3.0	30
284	Inhibition of growth of human ovarian cancer in nude mice by luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75 ). Fertility and Sterility, 1995, 63, 282-287.	1.0	30
285	Changes in subcellular distribution of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) after treatment with the LH-RH antagonist cetrorelix. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 961-965.	7.1	30
286	Effects of the growth hormone-releasing hormone (GH-RH) antagonist on brain functions in mice. Behavioural Brain Research, 2011, 224, 155-158.	2.2	30
287	Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14396-14401.	7.1	30
288	Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. Prostate, 2017, 77, 1036-1054.	2.3	30

#	Article	IF	CITATIONS
289	Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6726-6732.	7.1	30
290	Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH. Prostate, 1988, 12, 85-98.	2.3	29
291	Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitroâ~†. Peptides, 1999, 20, 843-850.	2.4	29
292	Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists. Expert Opinion on Investigational Drugs, 2003, 12, 1385-1394.	4.1	29
293	Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone–releasing hormone analogues AN-152 and AN-207. Fertility and Sterility, 2005, 83, 1125-1133.	1.0	29
294	New Treatment Approaches for Prostate Cancer Based on Peptide Analogues. European Urology, 2008, 53, 890-900.	1.9	29
295	Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Research and Treatment, 2009, 116, 273-279.	2.5	29
296	Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor. Journal of Molecular Endocrinology, 2010, 44, 127-134.	2.5	29
297	Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin. Lung, 2019, 197, 541-549.	3.3	29
298	Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2226-2231.	7.1	29
299	Antagonists of Growth Hormone-Releasing Hormone and Vasoactive Intestinal Peptide Inhibit Tumor Proliferation by Different Mechanisms: Evidence from in Vitro Studies on Human Prostatic and Pancreatic Cancers. Endocrinology, 2000, 141, 2120-2128.	2.8	29
300	Dissociation of MSH and ACTH Release in Man1. Journal of Clinical Endocrinology and Metabolism, 1973, 36, 770-772.	3.6	28
301	Polyfluoroalkylamine derivatives of luteinizing hormone-releasing hormone. Biochemistry, 1975, 14, 1848-1851.	2.5	28
302	Treatment of prostatic carcinoma with D-Trp-6-LH-RH: Plasma hormone levels after daily subcutaneous injections and periodic administration of delayed-release preparations. Prostate, 1985, 7, 271-282.	2.3	28
303	Behavioral effects of centrally administered LH-RH agonist in rats. Physiology and Behavior, 1992, 51, 601-605.	2.1	28
304	Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. , 2000, 88, 1384-1392.		28
305	Transcriptional Activation of Mouse sst2 Somatostatin Receptor Promoter by Transforming Growth Factor-1 <sup>2</sup> . Journal of Biological Chemistry, 2001, 276, 13461-13468.	3.4	28
306	Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity. International Journal of Cancer, 2002, 98, 624-629.	5.1	28

#	Article	IF	CITATIONS
307	Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4996-5001.	7.1	28
308	Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. International Journal of Cancer, 2004, 112, 570-576.	5.1	28
309	Growth hormoneâ€releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenanâ€induced chronic prostatitis. Prostate, 2018, 78, 970-980.	2.3	28
310	Treatment of advanced prostatic carcinoma with D-trp-6-LH-RH. Prostate, 1985, 7, 21-30.	2.3	27
311	Prolonged Suppression of Plasma LH Levels in Male Rats after a Single Injection of an LHâ€RH Agonist in Poly(DLâ€Lactideâ€Coâ€Glycolide) Microcapsules. Journal of Andrology, 1985, 6, 83-88.	2.0	27
312	Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: Comparison with other hormonal agents. Prostate, 1986, 9, 327-342.	2.3	27
313	Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate, 1993, 23, 165-178.	2.3	27
314	Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. European Journal of Endocrinology, 2004, 151, 391-396.	3.7	27
315	Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wildâ€ŧype p53 and decrease in p21 and mutant p53 proteins. Prostate, 2012, 72, 555-565.	2.3	27
316	Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2617-2622.	7.1	27
317	Relative Insensitivity of Rhesus Monkeys to the LH-Releasing Hormone (LH-RH). Journal of Clinical Endocrinology and Metabolism, 1973, 36, 372-374.	3.6	26
318	Stimulated release of hypothalamic growth hormone-releasing activity by morphine and pentobarbital. Molecular and Cellular Endocrinology, 1977, 6, 247-252.	3.2	26
319	Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anti-Cancer Drugs, 1992, 3, 109-116.	1.4	26
320	Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Research and Treatment, 1992, 21, 181-192.	2.5	26
321	Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. , 1999, 85, 2608-2615.		26
322	Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. Journal of Hepatology, 2005, 42, 230-237.	3.7	26
323	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. International Journal of Cancer, 2006, 118, 222-229.	5.1	26
324	Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist Cetrorelix with growth inhibition. International Journal of Oncology, 2009, 35, 789-96.	3.3	26

#	Article	IF	CITATIONS
325	Growth hormone releasing hormone induces the expression of nitric oxide synthase. Journal of Cellular and Molecular Medicine, 2011, 15, 1148-1155.	3.6	26
326	Mini-Review: Novel Therapeutic Strategies to Blunt Actions of Pneumolysin in the Lungs. Toxins, 2013, 5, 1244-1260.	3.4	26
327	Growth Hormone–Releasing Hormone Agonists Reduce Myocardial Infarct Scar in Swine With Subacute Ischemic Cardiomyopathy. Journal of the American Heart Association, 2015, 4, .	3.7	26
328	Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6067-6074.	7.1	26
329	Characterization of the Hormonal Responses to Luteinizing Hormone-Releasing Hormone (LH-RH) in Prepubertal and Adult Subjects. Pediatric Research, 1972, 6, 481-486.	2.3	25
330	EFFECT OF THYROXINE ON THE INACTIVATION OF THYROTROPHINâ€RELEASING HORMONE BY RAT AND HUMAN PLASMA. Clinical Endocrinology, 1976, 5, 323-330.	2.4	25
331	Effect of Somatostatin on Gastrointestinal Secretions and Peptic Ulcer Production in Cats. Scandinavian Journal of Gastroenterology, 1977, 12, 379-383.	1.5	25
332	Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cellsin vitro and intracellular production of cyclic adenosine monophosphate. International Journal of Cancer, 1995, 60, 694-700.	5.1	25
333	Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Cancer Letters, 2001, 171, 37-45.	7.2	25
334	Expression of growth hormone-releasing hormone in human primary endometrial carcinomas. European Journal of Endocrinology, 2002, 147, 381-386.	3.7	25
335	Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. Prostate, 2003, 56, 183-191.	2.3	25
336	Induction of apoptosis by AN-152, a cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), in LHRH-R positive human breast cancer cells is independent of multidrug resistance-1 (MDR-1) system. Breast Cancer Research and Treatment, 2004, 87, 255-264.	2.5	25
337	Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists. Current Medicinal Chemistry, 2008, 15, 314-321.	2.4	25
338	Bench-to-bedside development of agonists and antagonists of luteinizing hormone–releasing hormone for treatment of advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 270-274.	1.6	25
339	Receptors for d-Trp6-Luteinizing Hormone-Releasing Hormone, Somatostatin, and Insulin-Like Growth Factor I in MXT Mouse Mammary Carcinoma. Experimental Biology and Medicine, 1989, 192, 209-218.	2.4	24
340	Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the dunning R-3327H rat prostate cancer model. Prostate, 1992, 20, 297-310.	2.3	24
341	Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 15160-15165.	7.1	24
342	Partial Reversibility of Growth Hormone (GH) Deficiency in the GH-Releasing Hormone (GHRH) Knockout Mouse by Postnatal Treatment with a GHRH Analog. Endocrinology, 2005, 146, 1506-1513.	2.8	24

#	Article	IF	CITATIONS
343	A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides, 2010, 31, 1839-1846.	2.4	24
344	Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 1676-1685.	4.1	24
345	Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. Cell Cycle, 2014, 13, 2790-2797.	2.6	24
346	Targeting the $5\hat{a}\in^2$ -AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer. Expert Opinion on Therapeutic Targets, 2015, 19, 617-632.	3.4	24
347	Profound Actions of an Agonist of Growth Hormone–Releasing Hormone on Angiogenic Therapy by Mesenchymal Stem Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 663-672.	2.4	24
348	Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice. Scientific Reports, 2020, 10, 732.	3.3	24
349	Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways. Oncotarget, 2016, 7, 52661-52672.	1.8	24
350	An in Vivo Assay for Anti-LH-RH and Anti-FSH-RH Activity of Inhibitory Analogues of LH-RH <sup>â^—</sup> . Endocrinology, 1975, 96, 1130-1134.	2.8	23
351	Histological changes in dunning prostate tumors and testes of rats treated with LH-RH antagonist SB-75. Prostate, 1991, 18, 255-270.	2.3	23
352	LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro. Peptides, 1994, 15, 359-366.	2.4	23
353	Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. , 1996, 65, 870-874.		23
354	Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anti-Cancer Drugs, 1997, 8, 974-987.	1.4	23
355	Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer, 2001, 92, 1168-1176.	4.1	23
356	Effective Inhibition of Experimental Human Ovarian Cancers with a Targeted Cytotoxic Bombesin Analogue AN-215. Clinical Cancer Research, 2005, 11, 2408-2415.	7.0	23
357	Growth hormone-releasing hormone antagonist induces apoptosis of human endometrial cancer cells through PKCδ-mediated activation of p53/p21. Cancer Letters, 2010, 298, 16-25.	7.2	23
358	GH, But Not GHRH, Plays a Role in the Development of Experimental Autoimmune Encephalomyelitis. Endocrinology, 2011, 152, 3803-3810.	2.8	23
359	Mechanisms of synergism between antagonists of growth hormoneâ€releasing hormone and antagonists of luteinizing hormoneâ€releasing hormone in shrinking experimental benign prostatic hyperplasia. Prostate, 2013, 73, 873-883.	2.3	23
360	Involvement of the unfolded protein response in the protective effects of growth hormone releasing hormone antagonists in the lungs. Journal of Cell Communication and Signaling, 2021, 15, 125-129.	3.4	23

#	Article	IF	CITATIONS
361	New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget, 2015, 6, 9728-9739.	1.8	23
362	Melanin in the rat brain. Brain Research Bulletin, 1976, 1, 567-572.	3.0	22
363	Effect of thyrotropin-releasing hormone on gastro-intestinal secretions in dogs. Life Sciences, 1981, 29, 2289-2298.	4.3	22
364	Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anti-Cancer Drugs, 2002, 13, 949-956.	1.4	22
365	Inhibition of Growth of Experimental Human and Hamster Pancreatic Cancers In Vivo by a Targeted Cytotoxic Bombesin Analog. Pancreas, 2005, 31, 275-282.	1.1	22
366	Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4610-4615.	7.1	22
367	Antagonists of growth hormoneâ€releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate, 2010, 70, 1087-1093.	2.3	22
368	GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle, 2011, 10, 3714-3718.	2.6	22
369	Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle, 2012, 11, 2518-2525.	2.6	22
370	Inhibition of experimental smallâ€cell and nonâ€smallâ€cell lung cancers by novel antagonists of growth hormoneâ€releasing hormone. International Journal of Cancer, 2018, 142, 2394-2404.	5.1	22
371	Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer <i>in vivo</i> and <i>in vitro</i> through elevating p21 and ROS levels. Oncotarget, 2014, 5, 4567-4578.	1.8	22
372	Disappearance and excretion of labeled α-MSH in man. Pharmacology Biochemistry and Behavior, 1978, 9, 207-212.	2.9	21
373	Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. International Journal of Gastrointestinal Cancer, 1989, 4, 149-60.	0.4	21
374	Effective Treatment of Experimental Androgen Sensitive and Androgen Independent Intraosseous Prostate Cancer With Targeted Cytotoxic Somatostatin Analogue AN-238. Journal of Urology, 2004, 171, 911-915.	0.4	21
375	Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10628-10633.	7.1	21
376	Activation of Janus kinase/signal transducer and activator of transcription 3 pathway by growth hormone-releasing hormone. Cellular and Molecular Life Sciences, 2010, 67, 959-964.	5.4	21
377	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 742-749.	1.9	21
378	Agonists of growth hormone-releasing hormone (GHRH) inhibit human experimental cancers in vivo by down-regulating receptors for GHRH. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12028-12033.	7.1	21

#	Article	IF	CITATIONS
379	Synthesis and biological properties of ovine corticotropin-releasing factor (CRF). Life Sciences, 1982, 31, 429-435.	4.3	20
380	Biological Activity and Receptor Binding Characteristics to Various Human Tumors of Acetylated Somatostatin Analogs. Experimental Biology and Medicine, 1992, 200, 49-56.	2.4	20
381	Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. Anti-Cancer Drugs, 2009, 20, 553-558.	1.4	20
382	GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle, 2012, 11, 4203-4210.	2.6	20
383	Agonists of luteinizing hormone-releasing hormone in prostate cancer. Expert Opinion on Pharmacotherapy, 2013, 14, 2237-2247.	1.8	20
384	Gonadotropin releasing hormone (GnRH): Neuropharmacological studies. Life Sciences, 1975, 17, 1685-1691.	4.3	19
385	D-Trp-6-Luteinizing Hormone-Releasing Hormone Inhibits Hyperprolactinemia in Female Rats*. Endocrinology, 1985, 116, 2227-2231.	2.8	19
386	Somatostatin and its analog enhance the formation of human leukocyte migration inhibiting factor: Further evidence for immunomodulatory action of somatostatin. Peptides, 1987, 8, 951-952.	2.4	19
387	Effective treatment of advanced estrogen–independent MXT mouse mammary cancers with targeted cytotoxic LH–RH analogs. Breast Cancer Research and Treatment, 1999, 56, 265-274.	2.5	19
388	Apoptosis Versus Necrosis: Which Should Be the Aim of Cancer Therapy?. Proceedings of the Society for Experimental Biology and Medicine, 1999, 221, 87-88.	1.8	19
389	Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways. Peptides, 2001, 22, 879-886.	2.4	19
390	Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. Journal of Cancer Research and Clinical Oncology, 2001, 127, 645-652.	2.5	19
391	Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide. Prostate, 2001, 48, 188-199.	2.3	19
392	A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers. Oral Oncology, 2002, 38, 657-663.	1.5	19
393	The combination of antagonists of LHRH with antagonists of CHRH improves inhibition of androgen sensitive MDAâ€PCaâ€2b and LuCaPâ€35 prostate cancers. Prostate, 2007, 67, 1339-1353.	2.3	19
394	Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin. Anti-Cancer Drugs, 2008, 19, 349-358.	1.4	19
395	GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro. Peptides, 2012, 37, 63-68.	2.4	19
396	Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. Anti-Cancer Drugs, 2013, 24, 150-157.	1.4	19

#	Article	IF	CITATIONS
397	Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone. Oncotarget, 2013, 4, 422-432.	1.8	19
398	Determination of CRF activity in rats treated with Monase, dexamethasone, and morphine. American Journal of Physiology, 1965, 209, 1169-1174.	5.0	18
399	Comparison of the inhibition of histamine-and pentagastrin-stimulated gastric acid secretion by somatostatin in the cat. Agents and Actions, 1977, 7, 501-506.	0.7	18
400	Inhibitory Effects of the New Bombesin Receptor Antagonist RC-3095 on the Luteinizing Hormone Release in Rats. Neuroendocrinology, 1992, 56, 831-837.	2.5	18
401	In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses. Anti-Cancer Drugs, 2001, 12, 71-78.	1.4	18
402	Studies on the mechanism of action of a targeted chemotherapeutic drug in living cancer cells by two photon laser scanning microspectrofluorometry. Journal of Biomedical Optics, 2001, 6, 319.	2.6	18
403	STRUCTURE OF A HYPOTHALAMIC PEPTIDE POSSESSING GONADOTROPINâ€RELEASING ACTIVITY. International Journal of Peptide and Protein Research, 1972, 4, 421-430.	0.1	18
404	Inhibitory effects of antagonists of growth hormoneâ€releasing hormone on growth and invasiveness of PC3 human prostate cancer. International Journal of Cancer, 2013, 132, 755-765.	5.1	18
405	Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction. Frontiers in Physiology, 2014, 5, 259.	2.8	18
406	Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease. Cells, 2020, 9, 2331.	4.1	18
407	CHRH Antagonists Protect Against Hydrogen Peroxide-Induced Breakdown of Brain Microvascular Endothelium Integrity. Hormone and Metabolic Research, 2020, 52, 336-339.	1.5	18
408	Administration of LH-Releasing Hormone of Human Origin to Man. Journal of Clinical Endocrinology and Metabolism, 1971, 32, 287-289.	3.6	17
409	Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo. Metabolism: Clinical and Experimental, 1980, 29, 728-731.	3.4	17
410	An evaluation of intravenous, subcutaneous, and in vitro activity of new agmatine analogs of growth hormone-releasing hormone hGH-RH(1–29)NH2. Life Sciences, 1988, 42, 27-35.	4.3	17
411	Inhibition of GH Release in Rats by New Potent Antagonists of Growth Hormone-Releasing Hormone (GH-RH). Peptides, 1997, 18, 431-438.	2.4	17
412	Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas. Cancer, 2005, 104, 2266-2274.	4.1	17
413	Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. BJU International, 2007, 100, 2-4.	2.5	17
414	Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. Peptides, 2009, 30, 1643-1650.	2.4	17

#	Article	IF	CITATIONS
415	Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (ANâ€215) and a bombesin antagonist (RCâ€3095). International Journal of Cancer, 2010, 127, 1813-1822.	5.1	17
416	Receptors for luteinizing hormoneâ€releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix. Prostate, 2011, 71, 445-452.	2.3	17
417	Hormonal manipulation of benign prostatic hyperplasia. Current Opinion in Urology, 2013, 23, 17-24.	1.8	17
418	Growth hormone-releasing hormone receptor mediates cytokine production in ciliary and iris epithelial cells during LPS-induced ocular inflammation. Experimental Eye Research, 2019, 181, 277-284.	2.6	17
419	Agonistic analog of growth hormone–releasing hormone promotes neurofunctional recovery and neural regeneration in ischemic stroke. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	17
420	Lack of Luteolytic Effect of D-TRP-6-LH-RH in Hypophysectomized Rhesus Monkeys (Macaca mulatta)1. Biology of Reproduction, 1981, 25, 963-968.	2.7	16
421	Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH. Prostate, 1986, 9, 207-215.	2.3	16
422	Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma. Prostate, 1989, 14, 291-300.	2.3	16
423	Antagonists of bombesin/gastrin-releasing peptide as adjuncts to agonists of luteinizing hormone–releasing hormone in the treatment of experimental prostate cancer. Cancer, 1993, 72, 3263-3270.	4.1	16
424	Chronic Administration of a New Potent Agonist of Growth Hormone-Releasing Hormone Induces Compensatory Linear Growth in Growth Hormone-Deficient Rats: Mechanism of Action. Neuroendocrinology, 1996, 64, 169-176.	2.5	16
425	Direct action of growth hormone-releasing hormone agonist JI-38 on normal human fibroblasts: Evidence from studies on cell proliferation and c-myc proto-oncogene expression. Regulatory Peptides, 2001, 96, 119-124.	1.9	16
426	Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. Cancer Letters, 2005, 226, 123-131.	7.2	16
427	Expression of growth hormone–releasing hormone receptor splice variant 1 in primary human melanomas. Regulatory Peptides, 2008, 147, 33-36.	1.9	16
428	Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells. Peptides, 2012, 38, 275-281.	2.4	16
429	Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro. Targeted Oncology, 2013, 8, 281-290.	3.6	16
430	In Vivo Fluorescence Imaging and Urinary Monoamines as Surrogate Biomarkers of Disease Progression in a Mouse Model of Pheochromocytoma. Endocrinology, 2014, 155, 4149-4156.	2.8	16
431	Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1895-1900.	7.1	16
432	Extracorporeal apheresis therapy for Alzheimer disease—targeting lipids, stress, and inflammation. Molecular Psychiatry, 2020, 25, 275-282.	7.9	16

#	Article	IF	CITATIONS
433	Clinical Comparison of Natural LH-RH, Synthetic LH-RH, and Two Analogues of LH-RH. Journal of Clinical Endocrinology and Metabolism, 1974, 38, 801-804.	3.6	15
434	Antagonism of Receptors for Bombesin, Gastrin and Cholecystokinin in Pancreatic Secretion and Growth. Digestion, 1991, 48, 89-97.	2.3	15
435	Evaluation of binding of cytotoxic analogs of luteinizing hormone-releasing hormone to human breast cancer and mouse MXT mammary tumor. Breast Cancer Research and Treatment, 1992, 24, 147-158.	2.5	15
436	Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. Prostate, 2006, 66, 200-210.	2.3	15
437	Essential role of p21/waf1 in the mediation of the anti-proliferative effects of GHRH antagonist JMR-132. Journal of Molecular Endocrinology, 2008, 41, 389-392.	2.5	15
438	Growth hormone-releasing hormone antagonists abolish the transactivation of human epidermal growth factor receptors in advanced prostate cancer models. Investigational New Drugs, 2014, 32, 871-882.	2.6	15
439	LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. International Journal of Oncology, 2007, 30, 1485-92.	3.3	15
440	Prolonged Elevation of Luteinizing Hormone (Lh) after Intranasal Administration of an Analog of Lh-Releasing Hormone. Fertility and Sterility, 1976, 27, 1246-1249.	1.0	14
441	Clinical Studies with D-Trp6-Luteinizing Hormone-Releasing Hormone in Men with Hypogonadotropic Hypogonadism**Supported by a grant from Patronato de Investigaciones Endocrino-Metab³licas, Fundación General MediterrA¡nea, Madrid, Spain Fertility and Sterility, 1978, 30, 430-435.	1.0	14
442	Behavioral and hormonal effects of prolonged high doses of LHRH in male impotency. Peptides, 1981, 2, 115-121.	2.4	14
443	The effect of gastrointestinal hormones on the incorporation of tritiated thymidine in the pancreatic adenocarcinoma cell line (WD PaCa). International Journal of Gastrointestinal Cancer, 1989, 5, 191-201.	0.4	14
444	Fibrocystic disease of the breast in premenopausal women: Histohormonal correlation and response to luteinizing hormone releasing hormone analog treatment. American Journal of Obstetrics and Gynecology, 1991, 164, 1181-1189.	1.3	14
445	Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats. Peptides, 1992, 13, 905-911.	2.4	14
446	Effects of Combined Long-Term Treatment with a Growth Hormone-Releasing Hormone Analogue and a Growth Hormone Secretagogue in the Growth Hormone-Releasing Hormone Knock Out Mouse. Neuroendocrinology, 2005, 82, 198-207.	2.5	14
447	Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reproductive Biology and Endocrinology, 2010, 8, 54.	3.3	14
448	The effect of GHRH antagonists on human glioblastomas and their mechanism of action. International Journal of Cancer, 2010, 127, 2313-2322.	5.1	14
449	Rationally designed cyclic analogues of luteinizing hormone-releasing hormone: Enhanced enzymatic stability and biological properties. European Journal of Medicinal Chemistry, 2012, 58, 237-247.	5.5	14
450	Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma. Molecular and Cellular Endocrinology, 2013, 365, 212-222.	3.2	14

#	Article	IF	CITATIONS
451	Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer. Hormones and Cancer, 2017, 8, 314-324.	4.9	14
452	RAPID COMMUNICATION: Human Ovarian Cancers Express Somatostatin Receptors. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3509-3512.	3.6	14
453	Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study. Oncoscience, 2014, 1, 665-673.	2.2	14
454	Powerful Inhibition of Experimental Human Pancreatic Cancers by Receptor Targeted Cytotoxic LH-RH analog AEZS-108. Oncotarget, 2013, 4, 751-760.	1.8	14
455	Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression. Oncotarget, 2017, 8, 4410-4421.	1.8	14
456	Stereoisomers of luteinizing hormone-releasing hormone. Biochemical and Biophysical Research Communications, 1974, 59, 277-282.	2.1	13
457	LH-RH-containing nerve fibers in the brain of rats treated with sulpiride or reserpine. Brain Research, 1978, 152, 401-405.	2.2	13
458	Testosterone with an Inhibitory Analog of Luteinizing Hormone-Releasing Hormone in Adult Male Rhesus Monkeys*. Journal of Clinical Endocrinology and Metabolism, 1984, 59, 601-607.	3.6	13
459	The effect of β-(Tyr9)melanotropin-(9–18) on active avoidance behavior, electroconvulsive shock-induced amnesia and T-discrimination learning of rats. Peptides, 1986, 7, 11-13.	2.4	13
460	Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma. Journal of Cancer Research and Clinical Oncology, 1993, 119, 273-278.	2.5	13
461	Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. American Journal of Obstetrics and Gynecology, 1999, 181, 583-590.	1.3	13
462	Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anti-Cancer Drugs, 2005, 16, 159-165.	1.4	13
463	LH-RH receptors in human colorectal cancers: Unexpected molecular targets for experimental therapy. International Journal of Oncology, 2007, , .	3.3	13
464	The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. International Journal of Oncology, 2011, 39, 1025-32.	3.3	13
465	Luteinizing Hormone-Releasing Hormone (LHRH)-I Antagonist Cetrorelix Inhibits Myeloma Cell Growth <i>In vitro</i> and <i>In vivo</i> . Molecular Cancer Therapeutics, 2011, 10, 148-158.	4.1	13
466	Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice. Behavioural Brain Research, 2012, 233, 232-236.	2.2	13
467	Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning. Behavioural Brain Research, 2012, 233, 326-330.	2.2	13
468	Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1. Oncotarget, 2018, 9, 28745-28756.	1.8	13

#	Article	IF	CITATIONS
469	Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma. Oncotarget, 2013, 4, 1721-1728.	1.8	13
470	Melanocyte-stimulating Hormone Activity of Synthetic MSH and ACTH Peptides, in vivo and in vitro. Nature, 1965, 207, 978-979.	27.8	12
471	Unusual dose-related effect of an endorphin analog in a complex maze. Physiology and Behavior, 1980, 25, 959-962.	2.1	12
472	The origin and ultrastructural characteristics of corticotropin-releasing factor (CRF)-immunoreactive nerve fibers in the posterior pituitary of the rat. Cell and Tissue Research, 1985, 240, 467-71.	2.9	12
473	A clinical overview of carcinoid tumors: Perspectives for improvement in treatment using peptide analogs (Review). International Journal of Oncology, 2005, 26, 301.	3.3	12
474	Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: Low induction of multidrug resistance proteins. European Journal of Cancer, 2005, 41, 1824-1830.	2.8	12
475	Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. International Journal of Oncology, 2007, 30, 1019.	3.3	12
476	Potent agonists of growth hormone-releasing hormone. International Journal of Peptide and Protein Research, 2009, 39, 211-217.	0.1	12
477	Expression and possible implication of growth hormone–releasing hormone receptor splice variant 1 in endometriosis. Fertility and Sterility, 2009, 92, 47-53.	1.0	12
478	Gene expression of vasoactive intestinal peptide receptors in human lung cancer. International Journal of Oncology, 2011, 39, 1019-24.	3.3	12
479	Gastrin-Releasing Peptide Receptor Antagonism Induces Protection from Lethal Sepsis: Involvement of Toll-like Receptor 4 Signaling. Molecular Medicine, 2012, 18, 1209-1219.	4.4	12
480	Potentiating effects of GHRH analogs on the response to chemotherapy. Cell Cycle, 2015, 14, 699-704.	2.6	12
481	Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	12
482	LH-RH antagonists: Further analogs with ring-substituted aromatic residues. Peptides, 1981, 2, 251-253.	2.4	11
483	D-Tryptophan-6-luteinizing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia. Journal of Developmental and Physical Disabilities, 1982, 5, 171-178.	3.6	11
484	High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration. Regulatory Peptides, 1992, 41, 185-193.	1.9	11
485	Differential effects of LHRH and somatostatin analogs on human breast cancer. Journal of Surgical Research, 1992, 52, 6-14.	1.6	11
486	Combination treatment of nitrosamiee-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist. International Journal of Gastrointestinal Cancer, 1994, 16, 141-9.	0.4	11

#	Article	IF	CITATIONS
487	Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Research and Treatment, 1996, 40, 129-139.	2.5	11
488	Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness. International Journal of Oncology, 2001, 19, 571-7.	3.3	11
489	Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238. International Journal of Cancer, 2005, 114, 831-835.	5.1	11
490	Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: Antagonistic action of a growth-hormone-releasing hormone analog. International Journal of Oncology, 2005, 26, 1629-35.	3.3	11
491	Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine. International Journal of Peptide and Protein Research, 2009, 36, 499-505.	0.1	11
492	Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 781-786.	7.1	11
493	A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormoneâ€releasing hormone. British Journal of Haematology, 2018, 181, 476-485.	2.5	11
494	Expression of hypothalamic neurohormones and their receptors in the human eye. Oncotarget, 2017, 8, 66796-66814.	1.8	11
495	Effects of a long-acting LHRH agonist preparation on plasma gonadotropin and prolactin levels in castrated male rats and on the release of prolactin from ectopic pituitaries. Regulatory Peptides, 1986, 15, 219-228.	1.9	10
496	Delayed Release Formulation of the Somatostatin Analog RC-160 Inhibits the Growth Hormone (GH) Response to GH-Releasing Factor-(1-29)NH2and Decreases Elevated Prolactin Levels in Rats*. Endocrinology, 1988, 123, 1735-1739.	2.8	10
497	Prolactin-Lowering Effect of Luteinizing Hormone-Releasing Hormone Agonist Administration in Prolactinoma Patients. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 444-447.	3.6	10
498	SYNTHESIS AND BIOLOGICAL ACTIVITY OF POSITION 1 ANALOGS OF LHâ€RH. International Journal of Peptide and Protein Research, 1977, 9, 57-62.	0.1	10
499	Development of a radioimmunoassay for some agonists of growth hormoneâ€releasing hormone. International Journal of Peptide and Protein Research, 1993, 41, 162-168.	0.1	10
500	Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 387-395.	2.5	10
501	Differential immunostaining of various types of breast carcinomas for growth hormoneâ€releasing hormone receptor – Apocrine epithelium and carcinomas emerging as uniformly positive. Apmis, 2014, 122, 824-831.	2.0	10
502	Growth hormoneâ€releasing hormone receptor antagonists modify molecular machinery in the progression of prostate cancer. Prostate, 2018, 78, 915-926.	2.3	10
503	Expression of progenitor markers is associated with the functionality of a bioartificial adrenal cortex. PLoS ONE, 2018, 13, e0194643.	2.5	10
504	Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists. Investigational New Drugs, 2020, 38, 746-754.	2.6	10

#	Article	IF	CITATIONS
505	Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice. Scientific Reports, 2021, 11, 2530.	3.3	10
506	The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma. Oncotarget, 2020, 11, 175-187.	1.8	10
507	Alterations of ECFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. International Journal of Oncology, 2007, 30, 1019-28.	3.3	10
508	Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist. Oncology Reports, 2008, 20, 1289-94.	2.6	10
509	Use of GnRH in preference to LH-RH terminology in scientific papers. Human Reproduction, 2000, 15, 2059-2061.	0.9	9
510	Induction of Apoptosis in Pterygium Cells by Antagonists of Growth Hormone–Releasing Hormone Receptors. , 2018, 59, 5060.		9
511	Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction. Cardiovascular Research, 2023, 118, 3586-3601.	3.8	9
512	Selective uptake of the somatostatin analog RC-160 across the blood-brain tumor barrier of mice with KHT sarcomas. Anti-Cancer Drugs, 1992, 3, 519-524.	1.4	8
513	The Privileges of a Nobel Laureate. Fertility and Sterility, 1995, 64, 452-453.	1.0	8
514	Inhibition of Human Epithelial Ovarian Cancer Cell Growth in vitro by Somatostatin Analog RC-160. Oncology, 2000, 59, 45-49.	1.9	8
515	Inhibition of experimental U-118MG glioblastoma by targeted cytotoxic analogs of bombesin and somatostatin is associated with a suppression of angiogenic and antiapoptotic mechanisms. International Journal of Oncology, 2005, 27, 169.	3.3	8
516	Effect of somatostatin analogs on gastric acid secretion in dogs and rats. International Journal of Peptide and Protein Research, 1990, 36, 267-274.	0.1	8
517	Evaluation of biological activities of new LHâ€RH antagonists (Tâ€series) in male and female rats. International Journal of Peptide and Protein Research, 1993, 41, 66-73.	0.1	8
518	New analogs of human growth hormoneâ€releasing hormone (1â€29) with high and prolonged antagonistic activity. Chemical Biology and Drug Design, 1998, 51, 134-141.	1.1	8
519	Modulation of the Pancreatic Islet-Stress Axis as a Novel Potential Therapeutic Target in Diabetes Mellitus. Vitamins and Hormones, 2014, 95, 195-222.	1.7	8
520	Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1641-1649.	2.5	8
521	Structural Motif Descriptors as a Way To Elucidate the Agonistic or Antagonistic Activity of Growth Hormone–Releasing Hormone Peptide Analogues. ACS Omega, 2018, 3, 7432-7440.	3.5	8
522	Activity of the growth hormoneâ€releasing hormone antagonist MIA602 and its underlying mechanisms of action in sarcoidosisâ€rike granuloma. Clinical and Translational Immunology, 2021, 10, e1310.	3.8	8

#	Article	IF	CITATIONS
523	Improvement of cardiac and systemic function in old mice by agonist of growth hormoneâ€releasing hormone. Journal of Cellular Physiology, 2021, 236, 8197-8207.	4.1	8
524	Terminology for Luteinizing Hormone-Releasing Hormone Antagonists. Fertility and Sterility, 1995, 64, 226.	1.0	8
525	Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer. Oncotarget, 2016, 7, 52195-52206.	1.8	8
526	Differential expression of CHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. International Journal of Oncology, 2008, 33, 137-43.	3.3	8
527	The simultaneous determination of both the quantity and the fatty acid composition of the triglycerides in three to ten microliters of plasma. JAOCS, Journal of the American Oil Chemists' Society, 1966, 43, 2-6.	1.9	7
528	Hormonal Response to Synthetic Lh-Releasing Hormone (Lh-Rh) in Prepubertal, Pubertal, and Adult Human Males. Endocrine Research Communications, 1974, 1, 477-493.	0.5	7
529	Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues. Metabolism: Clinical and Experimental, 1978, 27, 1407-1410.	3.4	7
530	The interaction between β-[Tyr9]melanotropin-(9–18), haloperidol and amphetamine in different behavior tests of rats. Pharmacology Biochemistry and Behavior, 1982, 17, 15-18.	2.9	7
531	Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. International Journal of Oncology, 2008, , .	3.3	7
532	The Immunohistochemical Expression of Growth Hormone-Releasing Hormone Receptor Splice Variant 1 Is a Favorable Prognostic Marker in Colorectal Cancer. Molecular Medicine, 2009, 15, 242-247.	4.4	7
533	Effects of growth hormone-releasing hormone and its agonistic and antagonistic analogs in cancer and non-cancerous cell lines. International Journal of Oncology, 2010, 36, 1285-9.	3.3	7
534	Inhibitory Effects of GHRH Antagonists on Human GH-Secreting Adenoma Tissue. Neuroendocrinology, 2012, 96, 81-88.	2.5	7
535	Growth Hormone-Releasing Hormone Receptor Splice Variant 1 is Frequently Expressed in Oral Squamous Cell Carcinomas. Hormones and Cancer, 2012, 3, 172-180.	4.9	7
536	New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones. Asian Journal of Andrology, 2015, 17, 925.	1.6	7
537	Effects of an Antagonistic Analog of Growth Hormone-Releasing Hormone on Endometriosis in a Mouse Model and In Vitro. Reproductive Sciences, 2017, 24, 1503-1511.	2.5	7
538	Effects of growth hormone-releasing hormone receptor antagonist MIA-602Âin mice withÂemotional disorders: a potential treatment for PTSD. Molecular Psychiatry, 2021, 26, 7465-7474.	7.9	7
539	LHRH Agonists as Adjuncts to Somatostatin Analogs in the Treatment of Pancreatic Cancer. , 1990, , 203-210.		7

#	Article	IF	CITATIONS
541	Antagonist of growth hormone-releasing hormone MIA-690 attenuates the progression and inhibits growth of colorectal cancer in mice. Biomedicine and Pharmacotherapy, 2022, 146, 112554.	5.6	7
542	Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides, 2022, 150, 170716.	2.4	7
543	Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone. International Journal of Oncology, 2008, 32, 593-601.	3.3	7
544	Rat brain melanin at different ages and after various treatments. Brain Research Bulletin, 1979, 4, 793-797.	3.0	6
545	Effect of D-Leucine-6-Luteinizing Hormone-Releasing Hormone Ethylamide in Patients with Hypogonadotropic Hypogonadism with Anosmia. Fertility and Sterility, 1979, 32, 308-311.	1.0	6
546	Dynamics of injected somatostatin in blood of patients with hepatic failure and acromegaly. Peptides, 1980, 1, 257-259.	2.4	6
547	Use of Luteinizing Hormone - Releasing Hormone Analogs in the Treatment of Hormone-Dependent Tumors. Seminars in Reproductive Medicine, 1987, 5, 389-398.	1.1	6
548	Effect of long-term administration of an analog of growth hormone-releasing factor on the GH response in rats. Life Sciences, 1987, 40, 2437-2444.	4.3	6
549	Partial reversal of behavioral action of the agonist D-Trp-6-LH-RH by naloxone in mice. Life Sciences, 1990, 46, 463-470.	4.3	6
550	Evaluation of in vitro biological activity of new agmatine analogs of growth hormone-releasing hormone (GH-RH). Life Sciences, 1990, 46, 999-1005.	4.3	6
551	Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. International Journal of Oncology, 2006, 28, 1507.	3.3	6
552	GHRH and wound healing. Communicative and Integrative Biology, 2011, 4, 82-83.	1.4	6
553	Endocrine approaches to treatment of Alzheimer's disease and other neurological conditions. Peptides, 2015, 72, 154-163.	2.4	6
554	Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells. Peptides, 2016, 86, 153-161.	2.4	6
555	Concurrence of chromosome 3 and 4 aberrations in human uveal melanoma. Oncology Reports, 2017, 37, 1927-1934.	2.6	6
556	Agonist of growth hormone–releasing hormone enhances retinal ganglion cell protection induced by macrophages after optic nerve injury. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	6
557	Effects of β-/Tyr9/melanotropin-/9–18/ on apomorphine-induced stereotyped cage-climbing and on striatal dopamine release in mice. Comparative studies with amphetamine. Neuropeptides, 1982, 3, 91-96.	2.2	5
558	Effects of H-Phe-Ile-Tyr-His-Ser-Tyr-Lys-OH on passive and active avoidance behavior and on open-field activity of rats. Pharmacology Biochemistry and Behavior, 1982, 17, 633-637.	2.9	5

#	Article	IF	CITATIONS
559	Some Recollections of Early Clinical Studies on Hypothalamic Hormones: A Tale of a Successful International Collaboration. , 2001, 11, 341-349.		5
560	Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. International Journal of Oncology, 2002, 20, 397.	3.3	5
561	Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone. International Journal of Oncology, 2008, , .	3.3	5
562	Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2. Hormones and Cancer, 2015, 6, 100-106.	4.9	5
563	Protection of neonatal rat cardiac myocytes against radiation-induced damage with agonists of growth hormone-releasing hormone. Pharmacological Research, 2016, 111, 859-866.	7.1	5
564	Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 1-5.	1.2	5
565	Characterization of luteinizing hormone-releasing hormone receptor type I (LH-RH-I) as a potential molecular target in OCM-1 and OCM-3 human uveal melanoma cell lines. OncoTargets and Therapy, 2018, Volume 11, 933-941.	2.0	5
566	Possible Predictive Markers of Response to Therapy in Esophageal Squamous Cell Cancer. Pathology and Oncology Research, 2019, 25, 279-288.	1.9	5
567	Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. Anti-Cancer Drugs, 2012, 23, 906-913.	1.4	5
568	STIMULATORY AND INHIBITORY ANALOGS OF LH-RH. , 1981, , 19-30.		5
569	Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone. International Journal of Oncology, 2007, 31, 1223-30.	3.3	5
570	Effects of in vivo Treatment with an LHRH Antagonist Analog (D-PHE2-D-TRP3-D-PHE6) in the Immature Male Rat1. Biology of Reproduction, 1978, 19, 364-367.	2.7	4
571	Synthesis and biological activity of a cyclic pseudohexapeptide analog of somatostatin. Biochemical and Biophysical Research Communications, 1984, 120, 840-845.	2.1	4
572	Histological findings in the rat prostate cancer model during treatment with a luteinizing hormone agonist and novantrone. Prostate, 1987, 10, 291-302.	2.3	4
573	Systematic delivery of the luteinizing hormone-releasing hormone (LH-RH) antagonist cetrorelix (SB-75) via pulmonary instillation in the unanesthetized awake sheep. European Journal of Pharmaceutical Sciences, 1994, 2, 303-306.	4.0	4
574	Alterations in receptor-mediated kinases and phosphatases during carcinogenesis. Journal of Cancer Research and Clinical Oncology, 1995, 121, 141-149.	2.5	4
575	Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia. International Journal of Oncology, 2009, 35, 1053-9.	3.3	4
576	Comparison of GHâ€stimulation by GHâ€RH(1â€29)NH <sub>2</sub> and an agmatine <sup>29</sup> GHâ€RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats. International Journal of Peptide and Protein Research, 1993, 41, 246-249.	0.1	4

#	Article	IF	CITATIONS
577	Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity. International Journal of Peptide and Protein Research, 1995, 45, 561-566.	0.1	4
578	Search for novel therapies for triple negative breast cancers (TNBC): analogs of luteinizing hormone-releasing hormone (LHRH) and growth hormone-releasing hormone (GHRH). Hormone Molecular Biology and Clinical Investigation, 2012, 9, 87-94.	0.7	4
579	Antagonists of growth hormone releasing hormone (GHRH) given before whole body radiation lead to modulation of radiation response and organ-specific changes in the expression of angiogenesis. Journal of Radiation Oncology, 2012, 1, 389-396.	0.7	4
580	Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152). European Journal of Pharmaceutical Sciences, 2018, 123, 371-376.	4.0	4
581	Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma. Molecules, 2018, 23, 1535.	3.8	4
582	Expression of Somatostatin Receptor Subtypes (SSTR-1–SSTR-5) in Pediatric Hematological and Oncological Disorders. Molecules, 2020, 25, 5775.	3.8	4
583	Growth hormone-releasing hormone antagonistic analog MIA-690 stimulates food intake in mice. Peptides, 2021, 142, 170582.	2.4	4
584	Antagonists of Growth Hormone-Releasing Hormone Inhibit the Growth of Pituitary Adenoma Cells by Hampering Oncogenic Pathways and Promoting Apoptotic Signaling. Cancers, 2021, 13, 3950.	3.7	4
585	Expression of Growth Hormone-Releasing Hormone and Its Receptor Splice Variants in Primary Human Endometrial Carcinomas: Novel Therapeutic Approaches. Molecules, 2022, 27, 2671.	3.8	4
586	Effect of chronic administration of a new potent agonist of GH-RH(1–29)NH2 on linear growth and GH responsiveness in rats. Regulatory Peptides, 1996, 65, 197-201.	1.9	3
587	Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium. Life Sciences, 2003, 72, 2669-2674.	4.3	3
588	LHRH Analogs. , 2013, , 531-540.		3
589	CHRH Receptor Expression in Malignant Mixed Müllerian Tumors. International Journal of Gynecological Pathology, 2016, 35, 142-146.	1.4	3
590	LHRH receptor expression in sarcomas of bone and soft tissue. Hormone Molecular Biology and Clinical Investigation, 2016, 28, 105-111.	0.7	3
591	GHRH and wound healing. Communicative and Integrative Biology, 2011, 4, 82-3.	1.4	3
592	Tumorigenic transformation of human prostatic epithelial cell line RWPEâ€1 by growth hormoneâ€releasing hormone (GHRH). Prostate, 2022, 82, 933-941.	2.3	3
593	Effect of Ala-2-D-Trp-8-D-Cys-14-Somatostatin on the Arginine Induced Release of Insulin, gh and Glucagon in Normal men. Endocrine Research, 1984, 10, 39-48.	1.2	2
594	Method for Isolation of MMP-7-Ase Isoenzymes from Rat Muscle Tissue Extract. Preparative Biochemistry and Biotechnology, 1988, 18, 361-374.	0.5	2

#	Article	IF	CITATIONS
595	Actions of novel bombesin receptor antagonists on pancreatic secretion in. European Journal of Pharmacology, 1992, 214, 239-245.	3.5	2
596	Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone. International Journal of Oncology, 2007, 31, 1223.	3.3	2
597	The use of peptide analogs for the treatment of gastrointestinal, pancreatic, liver and urinary bladder cancers. Hormone Molecular Biology and Clinical Investigation, 2010, 1, 103-110.	0.7	2
598	Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer. Molecules, 2021, 26, 1253.	3.8	2
599	HIGH INCIDENCE OF RECEPTORS FOR LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AND LHRH RECEPTOR GENE EXPRESSION IN HUMAN PROSTATE CANCERS. Journal of Urology, 2000, , 623.	0.4	2
600	Antagonists of Growth Hormone–Releasing Hormone (GHRH) in Cancer. , 2006, , 483-489.		2
601	Physiology and Nature of Hypothalamic Regulatory Hormones. , 1977, , 1-42.		2
602	Impact of growth hormone-releasing hormone (GHRH) antagonist on Decidual stromal cell growth and apoptosis in vitro. Biology of Reproduction, 2021, , .	2.7	2
603	Endogenous phosphorylation in dunning prostate tumors of rats treated with LH-RH analogues. Prostate, 1984, 5, 605-611.	2.3	1
604	An LH-RH antagonist inhibits the behavioral effects of the agonist D-TRP-6-LH-RH in mice. Pharmacology Biochemistry and Behavior, 1992, 41, 665-668.	2.9	1
605	Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas. International Journal of Oncology, 2006, 29, 463.	3.3	1
606	Hypothalamic Releasing Hormones. , 2020, , 43-68.		1
607	Effects of growth hormone-releasing hormone agonistic analog MR-409 on insulin-secreting cells under cyclopiazonic acid-induced endoplasmic reticulum stress. Molecular and Cellular Endocrinology, 2021, 535, 111379.	3.2	1
608	in vivo inhibition of PCâ€3 human androgenâ€independent prostate cancer by a targeted cytotoxic bombesin analogue, ANâ€215. International Journal of Cancer, 2000, 88, 652-657.	5.1	1
609	A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC) Journal of Clinical Oncology, 2013, 31, 5062-5062.	1.6	1
610	GHRH-receptor as a new targetable biomarker in breast cancer and its correlation with ER/PR/HER2 status Journal of Clinical Oncology, 2015, 33, 576-576.	1.6	1
611	Analogs of Luteinizing Hormone-Releasing Hormone (LHRH) in Cancer. , 2006, , 421-427.		1
612	Effect of novel growth hormone-releasing hormone antagonists on growth of experimental renal cell carcinomas Journal of Clinical Oncology, 2013, 31, 469-469.	1.6	1

#	Article	IF	CITATIONS
613	A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer Journal of Clinical Oncology, 2017, 35, 210-210.	1.6	1
614	The effect of β-(Tyr9)melanotropin-(9-18) on the active avoidance and open-field behavior on rats pretreated with atropine or propranolol. Pharmacological Research Communications, 1984, 16, 369-379.	0.2	0
615	Bombesin and epidermal growth factor potentiate the effect of cytotoxic LH-RH analog AN-152 in vitro. International Journal of Oncology, 2002, 21, 1325.	3.3	О
616	Luteinizing hormone-releasing hormone antagonist Cetrorelix regulates the expression of Gαs and Gαi protein subunits and adenylate cyclase activity in rat ovary, breast and pituitary. International Journal of Oncology, 2004, 24, 725.	3.3	0
617	Letters To The Editors. Acta Cytologica, 2005, 49, 108-116.	1.3	Ο
618	Re: Editorial Comment on LHRH Antagonist Cetrorelix Reduces Prostate Size and Gene Expression of Proinflammatory Cytokines and Growth Factors in a Rat Model of Benign Prostatic Hyperplasia (Prostate 2011; 71: 736–747). Journal of Urology, 2013, 189, 1604-1605.	0.4	0
619	The effects of a growth hormone-releasing hormone antagonist and a gastrin-releasing peptide antagonist on intimal hyperplasia of the carotid artery after balloon injury in a diabetic rat modelâ~†. Artery Research, 2017, 19, 56.	0.6	0
620	Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog. Suizo, 2006, 21, 384-386.	0.1	0
621	Targeted Chemotherapy. , 2006, , 337-344.		0
622	Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer. , 2010, , 27-39.		0
623	A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer Journal of Clinical Oncology, 2012, 30, 60-60.	1.6	0
624	A phase I trial of AEZS-108 in castration- and taxane-resistant prostate cancer Journal of Clinical Oncology, 2012, 30, e15153-e15153.	1.6	0
625	Experimental therapy of PC-3 and DU-145 human androgen-independent prostate cancers with targeted cytotoxic analog of somatostatin AN-162 Journal of Clinical Oncology, 2013, 31, 236-236.	1.6	Ο
626	A randomized, phase II trial of AEZS-108 in chemotherapy refractory triple-negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer Journal of Clinical Oncology, 2013, 31, TPS11124-TPS11124.	1.6	0
627	Long-term response in a patient with urothelial cancer (UC) treated with AEZS-108 Journal of Clinical Oncology, 2013, 31, e15596-e15596.	1.6	0
628	Preclinical efficacy of growth hormone-releasing hormone antagonist MIA-602 for androgen-dependent and castration-resistant human prostate cancer Journal of Clinical Oncology, 2014, 32, 221-221.	1.6	0
629	Phase 1 trial of zoptarelin doxorubicin (Zop-Dox) in advanced unresectable or metastatic urothelial carcinoma (UC) patients who failed platinum-based chemotherapy Journal of Clinical Oncology, 2014, 32, e15517-e15517.	1.6	0
630	Expression of GHRH-R in primary and metastatic mammary carcinomas Journal of Clinical Oncology, 2014, 32, 19-19.	1.6	0

#	Article	IF	CITATIONS
631	Treatment of urinary bladder cancers by growth hormone-releasing hormone antagonists: A preclinical report Journal of Clinical Oncology, 2016, 34, 433-433.	1.6	0
632	Immunohistochemical expression of receptors for luteinizing hormone-releasing hormone (LHRHR) in muscle-invasive Urothelial carcinoma of urinary bladder: a potential predictive marker for targeted cytotoxic LHRH hybrid analogs. Surgical and Experimental Pathology, 2020, 3, .	0.6	0